MedAvail Holdings, Inc. reaffirmed financial guidance for the full year 2022. The company affirmed its previously issued guidance for full year 2022 revenue to be at least $42 million, representing growth of at least 90% over full year 2021 revenue. The company also affirms its guidance of 40 new net dispensing deployments for full year 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0002 USD | -.--% | -.--% | -100.00% |
May. 06 | Motion for Asset Sale Filed by MedAvail Holdings, Inc. | CI |
May. 03 | Notice of Successful Bidder Filed by MedAvail Holdings, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
-100.00% | 322 | |
+16.45% | 86.87B | |
+18.70% | 70.3B | |
+23.09% | 38.41B | |
+27.62% | 35.39B | |
+9.72% | 27.78B | |
+9.17% | 28.13B | |
+4.71% | 27.14B | |
+20.97% | 25.57B | |
+9.30% | 24.11B |
- Stock Market
- Equities
- MYOS Stock
- News MedAvail Holdings, Inc.
- MedAvail Holdings, Inc. Reaffirms Financial Guidance for the Full Year 2022